Department of Hematology and Blood Banking, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran.
School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Cancer Gene Ther. 2023 Jul;30(7):936-954. doi: 10.1038/s41417-023-00597-z. Epub 2023 Feb 28.
Gene editing-based therapeutic strategies grant the power to override cell machinery and alter faulty genes contributing to disease development like cancer. Nowadays, the principal tool for gene editing is the clustered regularly interspaced short palindromic repeats-associated nuclease 9 (CRISPR/Cas9) system. In order to bring this gene-editing system from the bench to the bedside, a significant hurdle remains, and that is the delivery of CRISPR/Cas to various target cells in vivo and in vitro. The CRISPR-Cas system can be delivered into mammalian cells using various strategies; among all, we have reviewed recent research around two natural gene delivery systems that have been proven to be compatible with human cells. Herein, we have discussed the advantages and limitations of viral vectors, and extracellular vesicles (EVs) in delivering the CRISPR/Cas system for cancer therapy purposes.
基于基因编辑的治疗策略赋予了我们超越细胞机制的能力，能够改变导致疾病发展的错误基因，如癌症。如今，基因编辑的主要工具是成簇规律间隔短回文重复序列相关的核酸酶 9（CRISPR/Cas9）系统。为了将这种基因编辑系统从实验室带到临床，仍然存在一个重大障碍，那就是将 CRISPR/Cas 递送到体内和体外的各种靶细胞中。CRISPR-Cas 系统可以使用各种策略递送到哺乳动物细胞中；在所有这些策略中，我们回顾了最近围绕两种已被证明与人类细胞兼容的天然基因传递系统的研究。在此，我们讨论了病毒载体和细胞外囊泡（EVs）在递送 CRISPR/Cas 系统用于癌症治疗方面的优缺点。
